• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Sustained-release formula in works for neovascular AMD


PR Pharmaceuticals Inc. (PRP) and OSI Pharmaceuticals entered an agreement to develop a sustained-release formula of pegaptanib sodium injection (Macugen), a novel treatment for neovascular age-related macular degeneration.

The agreement gives OSI and its development and marketing partner Pfizer access to PRP's proprietary ProPhase technology for encapsulating pegaptanib sodium injection for ophthalmic use. OSI's eye disease unit, Eyetech Pharmaceuticals, is responsible for clinical development activities and has the right to manufacture and commercialize the resulting product.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.